Sareum Holdings (SAR) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 May 2024 07:00 AM
RNS
Appointment of Sole Broker
07 May 2024 02:10 PM
RNS
Exercise of Warrants
23 Apr 2024 07:00 AM
RNS
Final Issue of RiverFort Subscription Shares
19 Apr 2024 11:35 AM
RNS
Issue of RiverFort Subscription Shares
15 Apr 2024 03:28 PM
RNS
Issue of RiverFort Subscription Shares
09 Apr 2024 04:00 PM
RNS
Issue of RiverFort Subscription Shares
04 Apr 2024 02:38 PM
RNS
Completion of Equity Fundraise
02 Apr 2024 04:51 PM
RNS
Result of WRAP Retail Offer
02 Apr 2024 07:00 AM
RNS
Increase in size of WRAP Retail Offer
28 Mar 2024 07:02 AM
RNS
WRAP Retail Offer
28 Mar 2024 07:01 AM
RNS
Equity Fundraise
28 Mar 2024 07:00 AM
RNS
Sareum Half-Year Report
15 Mar 2024 07:00 AM
RNS
New Patent Allowance
12 Mar 2024 01:30 PM
RNS
Notice of Interim Results and Trading Update
15 Feb 2024 07:00 AM
RNS
Update on SDC-1801 Clinical Trial Progress
02 Jan 2024 07:00 AM
RNS
Development and commercialisation licence SRA737
14 Dec 2023 03:35 PM
RNS
Results of AGM
14 Dec 2023 07:00 AM
RNS
Annual General Meeting Statement
23 Nov 2023 07:00 AM
RNS
Drawdown of Equity Prepayment Facility
21 Nov 2023 07:00 AM
RNS
Notice of AGM, Annual Report and Accounts
09 Nov 2023 07:00 AM
RNS
Initiation of food effects study for SDC-1801
08 Nov 2023 03:03 PM
RNS
Director Dealings
03 Nov 2023 07:05 AM
RNS
Sareum enhances SDC-1801 patent protection
02 Nov 2023 02:48 PM
RNS
Exercise of Share Options and Director Dealings
09 Oct 2023 07:00 AM
RNS
Final Results for the Year Ended 30 June 2023
03 Oct 2023 07:00 AM
RNS
Notice of Results and Investor Presentation
06 Sep 2023 07:00 AM
RNS
Director's Dealing
05 Sep 2023 07:00 AM
RNS
Director Dealing
04 Sep 2023 07:00 AM
RNS
Dosing of first subjects in MAD Phase 1a trial
16 Aug 2023 07:00 AM
RNS
Update on financial and operational progress
03 Aug 2023 07:00 AM
RNS
Equity Prepayment Facility of up to £5 million
26 Jun 2023 07:00 AM
RNS
Sareum Announces Two New Granted Patents
06 Jun 2023 07:00 AM
RNS
Dosing commences in Phase 1a trial of SDC-801
18 May 2023 07:00 AM
RNS
Phase 1a clinical trial for SDC-1801
05 May 2023 09:20 AM
RNS
Approval to initiate Phase 1 clinical trial
22 Mar 2023 07:00 AM
RNS
Half-Year Report
15 Mar 2023 07:01 AM
RNS
Update on SDC-1801
15 Mar 2023 07:00 AM
RNS
Notice of Half-Year Results
06 Mar 2023 07:00 AM
RNS
Update on SRA737
29 Dec 2022 03:14 PM
RNS
Director/PDMR Shareholding
16 Dec 2022 03:29 PM
RNS
Results of AGM
16 Dec 2022 07:00 AM
RNS
AGM Statement
24 Nov 2022 07:00 AM
RNS
Notice of AGM, Annual Report and Accounts
21 Nov 2022 07:00 AM
RNS
Sareum notes publication of SRA737 clinical data
09 Nov 2022 04:41 PM
RNS
Second Price Monitoring Extn
09 Nov 2022 04:35 PM
RNS
Price Monitoring Extension
09 Nov 2022 02:05 PM
RNS
Second Price Monitoring Extn
09 Nov 2022 02:00 PM
RNS
Price Monitoring Extension
09 Nov 2022 11:05 AM
RNS
Second Price Monitoring Extn
09 Nov 2022 11:00 AM
RNS
Price Monitoring Extension

Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.

It listed on AIM in 2004 under the ticker SAR.

UK 100

Latest directors dealings